Musk's new crown research is published in the journal of Nature

SpaceX and Tesla CEO Elon Musk recently crossed the border again and published a new coronavirus research paper in the international academic journal Nature Communications.

The corresponding author of the paper, assistant professor at Harvard Medical School, and clinician at Brigham and Women’s Hospital, Eric Nilles, told The Paper that this study found that there seems to be significant individual differences in the immune response of patients infected with the new coronavirus, and some individuals have developed them.

"This may affect the durability of the immune response, the risk of reinfection, and the severity of reinfection.

The research is entitled "Discrete SARS-CoV-2 antibody titers track with functional humoral stability" ("Discrete SARS-CoV-2 antibody titers track with functional humoral stability").

There are 30 authors in the paper, and Musk is one of the co-authors.

Eric Nilles told The Paper journalists that Musk provided important input for the planning of this research.

Musk has repeatedly spoken about the new crown epidemic in public.

Musk also disagrees with the implementation of blockade measures to prevent and control the epidemic.

The "Nature-Communications" paper mentioned that although there is evidence that the antibody response of people infected with the new coronavirus persists, cases of re-infection have also begun to appear.

To start the experiment, the research team recruited 4,300 volunteers from SpaceX, which is led by Musk.

Through seroepidemiological studies, the team identified 120 positive patients.

The paper stated that cases confirmed by PCR nucleic acid testing appear to have higher antibody titers, most likely because individuals with symptoms related to new coronary pneumonia are more likely to be tested.

Among the volunteers with positive serum antibodies, the research team conducted a longitudinal antibody analysis, with an average sampling interval of 39.

They observed that at least 83% (10/12) of individuals in the high-titer group had specific T cells against the new coronavirus, while only 10% (1/10) of the individuals in the low-titer group had specific T cells.

T cells are white blood cells that specifically recognize viruses and are an important part of the immune system.

According to the study, the above findings indicate that the new coronavirus-specific T cells are not detectable in all patients infected with the new coronavirus, and they cannot be selectively enhanced in individuals with weak humoral immune responses.

Studies have observed that there is an on-off relationship between antibody titer and function.
In this relationship, an activity threshold defined by the antibody level is required to trigger a strong humoral and cellular immune response.

The corresponding author of the paper, Eric Nilles, explained to The Paper that the threshold here refers to the level of antibody titer that can cause a wide range of immune responses (including neutralization and T cell responses).

He said that this is a laboratory-based immune response study.
In order to know exactly how the above findings affect the body's immunity to the new coronavirus, they are studying the immunity of cases of re-infection.